Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Other Accumulated Expenses: 2023-2024

Historic Other Accumulated Expenses for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $3.2 million.

  • Contineum Therapeutics' Other Accumulated Expenses fell 12.54% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 12.54%. This contributed to the annual value of $3.2 million for FY2024, which is 103.82% up from last year.
  • Per Contineum Therapeutics' latest filing, its Other Accumulated Expenses stood at $3.2 million for FY2024, which was up 103.82% from $1.5 million recorded in FY2023.
  • In the past 5 years, Contineum Therapeutics' Other Accumulated Expenses ranged from a high of $3.2 million in FY2024 and a low of $1.5 million during FY2023.
  • For the 2-year period, Contineum Therapeutics' Other Accumulated Expenses averaged around $2.3 million, with its median value being $2.3 million (2023).
  • Data for Contineum Therapeutics' Other Accumulated Expenses shows a peak YoY surged of 103.82% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Contineum Therapeutics' Other Accumulated Expenses stood at $1.5 million in 2023, then spiked by 103.82% to $3.2 million in 2024.